Product Description
Pfizer was developing pf-04878691, an oral TLR7 Agonist for Hepatitis C Virus. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00810758)
Mechanisms of Action: TLR7 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Hepatitis C
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
B1201002 | P1 |
Completed |
Hepatitis C |
2009-11-01 |